Looking into entering the German market with your Phase II or Phase II study? In this webinar, you will learn how to optimally leverage the Early G-BA Advice process for your Market Access strategy. Early consultations with the Federal Joint Committee (G-BA) are a crucial step in evaluating and optimizing your approval-related studies.

However, many Market Access professionals in pharmaceutical companies face challenges after these consultations, often due to unresolved questions and uncertainties.

In this webinar, we will provide insights and practical solutions to help you effectively overcome these obstacles. We will offer tips on how to best prepare for and conduct Early G-BA consultations, as well as how to fully understand the G-BA’s requirements and incorporate them into your study designs.

Key topics

• How to effectively prepare for Early G-BA consultations to ensure a successful outcome.
• Practical strategies for implementing G-BA feedback in clinical study designs.
• Common pitfalls and how to navigate uncertainties following G-BA consultations.

Speaker

• Dr Stefan Baumann, Market Access Consultant
• Hans Hirsch, Business Development Manager